Yue Xiang Yue Health | March 2026 Prospectus Filing Announcement
IASO Biotechnology
Cancer Treatment New Drug Developer
E-Health Now
Lifecycle Intelligent Health Management Service Provider
Healthgen Biotech
Research and Product Developer of Plant-derived Recombinant Protein Expression Technology
Century Healthcare
Medical Device Manufacturer, R&D, and Distributor
In March, the industry's grand event BIOCHINA 2026 opened in Suzhou. Mr. Zhu Pai, CEO of Efund Capital, was invited to attend and participated in a roundtable forum titled "LP-GP Ecosystem: 'Synergy' in Policy, Capital, and Innovation" on the 13th, engaging in an in-depth dialogue with industry peers. Meanwhile, portfolio companies of Efund Capital also shone brightly at the conference: companies like IASO Bio made significant appearances, showcasing the cutting-edge strength of China's innovative pharmaceutical enterprises to the industry.
Outside the conference, numerous invested companies of Everfront Capital are also making significant progress in their respective fields, achieving critical breakthroughs one after another and demonstrating vigorous development momentum.
01
Progress of Portfolio Companies' IPOs and Financing
E-Health Now
· AI Agent Reconstructs the Ecosystem of Medical Health Management Services
E-Health Now
· AI Agent Reconstructs the Ecosystem of Medical Health Management Services
Recently, E-Health Now, a leading artificial intelligence digital health service technology group in China, officially announced the completion of several hundred million RMB in financing.DThis round of financing was jointly led by EF Capital, Yahelon, Ventech China, and Fengqiao Capital.
02
Clinical and Commercial Dynamics of Invested Companies
。
Healthgen Biotech
· Aflumin® Phase IV Clinical Trial Completes First Dosing
Healthgen Biotech
· Aflumin® Phase IV Clinical Trial Completes First Dosing
Recently, Healthgen Biotech's recombinant human albumin (rice) Oufumin® "In Hypoalbuminemia and/or the safety and effectiveness in patients with insufficient blood volume requiring emergency treatment"IV The first patient was enrolled and the first dose was administered in the Phase I clinical study.IV Entering the substantive clinical research stage.
Recently, Healthgen Biotech's recombinant human albumin (rice) Oufumin® "In Hypoalbuminemia and/or the safety and effectiveness in patients with insufficient blood volume requiring emergency treatment"IV The first patient was enrolled and the first dose was administered in the Phase I clinical study.IV Entering the substantive clinical research stage.
。
Century Healthcare
· Completed by multiple hospitalsWanshi Anru Technique
Century Healthcare
· Completed by multiple hospitalsWanshi Anru Technique
Recently, Taiyuan Aier Eye Hospital in Shanxi Province completed the first case of cataract surgery using the Wan Shi An lens in China, and it was also the first case in Shanxi Province.®Ultra-EDoFExtended Depth of Focus Intraocular Lens Implantation Surgery; Beijing Huaxia People's Eye Hospital Completed the First Batch in China for All-View Comfort®Ultra-EDoF Implantation Surgery of Artificial Crystalline Lens; Zhengzhou Apex Eye Hospital Implants the First Diffractive TypeEDoFIntraocular Lens (VisionEase)®Ultra-EDoF), etc.
。
Innermedical
· "Gemini" Lands at Macao Union Hospital, Supporting a New Benchmark for Precision Medicine in the Greater Bay Area
Innermedical
· "Gemini" Lands at Macao Union Hospital, Supporting a New Benchmark for Precision Medicine in the Greater Bay Area
Innermedical"Gemini"Mini-probe Endoscopic UltrasoundOfficially launched at the Macao Medical Center of Peking Union Medical College Hospital, injecting innovative momentum into the high-quality development of Macao and the Guangdong-Hong Kong-Macao Greater Bay Area healthcare sector.
· Three Ministries Lead the Way: National Electronic Gastrointestinal Endoscopy Promotion Project Officially Launched
· Three Ministries Lead the Way: National Electronic Gastrointestinal Endoscopy Promotion Project Officially Launched
On March 28, the "2025 High-End Medical Equipment Promotion and Application Project – Endoscopic Ultrasound Promotion and Application Project," jointly promoted by three ministries of China’s Ministry of Industry and Information Technology, National Health Commission, and National Medical Products Administration, was officially launched. The project is led by West China Hospital of Sichuan University as the lead hospital and Innermedical as the lead enterprise, with the collaboration of 13 participating hospitals and 12 cooperative hospitals working together.
On March 28, the "2025 High-End Medical Equipment Promotion and Application Project – Endoscopic Ultrasound Promotion and Application Project," jointly promoted by three ministries of China’s Ministry of Industry and Information Technology, National Health Commission, and National Medical Products Administration, was officially launched. The project is led by West China Hospital of Sichuan University as the lead hospital and Innermedical as the lead enterprise, with the collaboration of 13 participating hospitals and 12 cooperative hospitals working together.
。
Kash Biotech
· Debut at 2026 CACLP
Kash Biotech
· Debut at 2026 CACLP
3Month21Day to23On [date], the 25th China International Medical Laboratory and Transfusion Instruments and Reagents Expo was held in Xiamen. Kaishi Biotech, as a leading domesticCDMOService providers, with multiple core achievements, made a significant appearance.
。
HaploX
· Exclusive Strategic Cooperation Reached with IASO Bio
HaploX
· Exclusive Strategic Cooperation Reached with IASO Bio
Recently,HaploX and WeiYi Biotech Exclusive Strategic Cooperation Signing Ceremony Successfully Held. This cooperation重磅推出“Fully Enclosed Zero-Contamination Medium-to-High Throughput Sequencing Solution”。
。
TyneoBio
· New Drug for Preventing Infant RSV Infection - RSV Monoclonal Antibody Accelerates Market Launch Process
TyneoBio
· New Drug for Preventing Infant RSV Infection - RSV Monoclonal Antibody Accelerates Market Launch Process
3Month2The recombinant long-acting anti-respiratory syncytial virus fully human monoclonal antibody - Retvebimab Injection, developed by Zhuhai Tanox BioPharma, has been officially included in the priority review and approval process of the Center for Drug Evaluation under the National Medical Products Administration.
03
Approval Status of New Drugs and Devices from Invested Companies
。
Yinming Bio
· China's First, World's FirstRecombinant Botulinum Toxin Type AApproved for Marketing
Yinming Bio
· China's First, World's FirstRecombinant Botulinum Toxin Type AApproved for Marketing
On March 25, the National Medical Products Administration officially released information, stating thatChongqing Yuyan Pharmaceutical(Developed by Eminence Biotech Holdings)Injectable Recombinant Botulinum Toxin Type A(Approval No. S20260019) has been approved for marketing, isChina's First, World's FirstBotulinum Toxin Type A produced using recombinant technology.
。
Huanma Biotech
· HM2003 Injection Receives FDA Clinical Trial Approval and Pediatric Rare Disease Designation
Huanma Biotech
· HM2003 Injection Receives FDA Clinical Trial Approval and Pediatric Rare Disease Designation
3 Month11 Day,Cycle Code BiotechAnnouncing its independently developed second core annularRNAInnovative Drugs HM2003 Injection solution officially approved by the U.S. Food and Drug Administration (FDA) Clinical Trial Permit.
。
Hannuo Medical
· China-Made "Artificial Lung" Receives U.S. FDA Approval
Hannuo Medical
· China-Made "Artificial Lung" Receives U.S. FDA Approval
3Month16Day,The core product of the extracorporeal membrane oxygenation system independently developed by Hannover Medical"Disposable Membrane Oxygenator" Officially Approved by the U.S. Food and Drug Administration (FDA) of510(k)Access Permit.
。
IASO Bio
· IASO Bio's CAR-T Drug Idecabtagene Vicleucel Injection for the Treatment of 2/3 Line Multiple Myeloma Receives Implied Approval from Japan's PMDA for Clinical Trial Application
IASO Bio
· IASO Bio's CAR-T Drug Idecabtagene Vicleucel Injection for the Treatment of 2/3 Line Multiple Myeloma Receives Implied Approval from Japan's PMDA for Clinical Trial Application
3Month24The other day, IASO Bio announcedIts independently developed fully human targetedBCMA CAR-TCell therapy product Icarus Injection (Fucaso) The clinical trial application has received tacit approval from Japan's Pharmaceuticals and Medical Devices Agency.
。
Spiritual Essence Origin
· World’s First TCR×CD3 Bispecific Antibody Targeting RAS G12V Mutation Approved for U.S. Clinical Trials
Spiritual Essence Origin
· World’s First TCR×CD3 Bispecific Antibody Targeting RAS G12V Mutation Approved for U.S. Clinical Trials
3Month12Day, Spirit BiotechES502Injection Solution ObtainedFDAApprovalIPhase clinical trial, used for treating withRAS G12VPatients with advanced solid tumors harboring mutations.
。
MicroCore Biotech
· World's First! Chipscreen Biosciences' Combination Therapy for Type 2 Diabetes, Ciglitazone and Metformin Sustained-Release Tablets, Approved for Clinical Trials
MicroCore Biotech
· World's First! Chipscreen Biosciences' Combination Therapy for Type 2 Diabetes, Ciglitazone and Metformin Sustained-Release Tablets, Approved for Clinical Trials
3Month16Date, Chipscreen Biosciences and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceuticals announced that the company's self-developed treatment2Clinical Trial Application for Sodium Siglitazar and Metformin Hydrochloride Sustained-Release Tablets for Type Diabetes has been approved by the National Medical Products Administration (NMPA).NMPA) Approval.
3Month16Date, Chipscreen Biosciences and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceuticals announced that the company's self-developed treatment2Clinical Trial Application for Sodium Siglitazar and Metformin Hydrochloride Sustained-Release Tablets for Type Diabetes has been approved by the National Medical Products Administration (NMPA).NMPA) Approval.
· Original Brain-Penetrant PRMT5-MTA Inhibitor CS08399 Approved for Clinical Trials
· Original Brain-Penetrant PRMT5-MTA Inhibitor CS08399 Approved for Clinical Trials
3Month13Recently, Chengdu Chipscreen Pharmaceuticals, a wholly-owned subsidiary of Chipscreen Biosciences, announced that the company's self-developed1New-type Original DrugCS08399Tablets for the treatment of methionine adenosyltransferase(MTAP)Clinical Trial Applications for Missing Solid Tumors and Lymphomas (IND) has been approved by the National Medical Products Administration.
3Month13Recently, Chengdu Chipscreen Pharmaceuticals, a wholly-owned subsidiary of Chipscreen Biosciences, announced that the company's self-developed1New-type Original DrugCS08399Tablets for the treatment of methionine adenosyltransferase(MTAP)Clinical Trial Applications for Missing Solid Tumors and Lymphomas (IND) has been approved by the National Medical Products Administration.
04
Honors of Invested Enterprises
Selected for the 11th Batch of the "Directory of Excellent Domestic Medical Device Products"
· BIOPSEE® Beixi® Confocal Microendoscope, BIOPSEE® Beixi® Ultra-thin Probe-type
Selected for the 11th Batch of the "Directory of Excellent Domestic Medical Device Products"
· BIOPSEE® Beixi® Confocal Microendoscope, BIOPSEE® Beixi® Ultra-thin Probe-type
Selected as a key specialized and innovative small and medium-sized enterprise in Zhejiang Province by the Zhejiang Provincial Department of Economy and Information Technology for 2026 ("Key Provincial Specialized Enterprise").
· Hangzhou Huamai, Nyloon Biotech
Selected as a key specialized and innovative small and medium-sized enterprise in Zhejiang Province by the Zhejiang Provincial Department of Economy and Information Technology for 2026 ("Key Provincial Specialized Enterprise").
· Hangzhou Huamai, Nyloon Biotech
Awarded by the National Center for ADR Monitoring as an Outstanding Enterprise in the 2025 Drug, Device, and Cosmetic ADR Monitoring and Evaluation Work
· Real Biotech
Awarded by the National Center for ADR Monitoring as an Outstanding Enterprise in the 2025 Drug, Device, and Cosmetic ADR Monitoring and Evaluation Work
· Real Biotech
Debut at AACR 2026: Poster Presentation of Two Research Findings
· Tian Gang Medical
Debut at AACR 2026: Poster Presentation of Two Research Findings
· Tian Gang Medical
AwardedThird Prize in the First Guangdong-Hong Kong-Macao Greater Bay Area Entrepreneurship Competition
· Huayuan Regenerative Medicine
AwardedThird Prize in the First Guangdong-Hong Kong-Macao Greater Bay Area Entrepreneurship Competition
· Huayuan Regenerative Medicine
"Selected as one of the 'Top Ten Researches in Breast Cancer Field 2025'"
· Huahao Zhongtian Utidelone for the Treatment of Brain Metastases in Breast Cancer
"Selected as one of the 'Top Ten Researches in Breast Cancer Field 2025'"
· Huahao Zhongtian Utidelone for the Treatment of Brain Metastases in Breast Cancer
RongAwarded 2026 Forbes China Industry Development Leading Enterprise
· Aomer Pharma, Genuine Biotech
RongAwarded 2026 Forbes China Industry Development Leading Enterprise
· Aomer Pharma, Genuine Biotech
RongPublished in the international professional journal of critical care medicine, "ICU Management & Practice"
· Hannuo Medical Lifemotion® ECMO System
RongPublished in the international professional journal of critical care medicine, "ICU Management & Practice"
· Hannuo Medical Lifemotion® ECMO System
05
Yifeng Honor
▷ Pencil News
Everbright Capital-
Top 20 Most Active Investment Institutions in Healthcare for 2025
▷First New Voice
Everbright Capital-
2025The Most Active Venture Capital Institution in China for the YearTOP30
2025Best Investment of the Year in ChinaInstitution
CEO of Efund Capital, Zhu Pai-
Top 30 Best Young Investors in China for 2025
05
Yifeng Honor
▷ Pencil News
Everbright Capital-
Top 20 Most Active Investment Institutions in Healthcare for 2025
▷First New Voice
Everbright Capital-
2025The Most Active Venture Capital Institution in China for the YearTOP30
2025Best Investment of the Year in ChinaInstitution
CEO of Efund Capital, Zhu Pai-
Top 30 Best Young Investors in China for 2025
06
Yifeng Milestones
Yifeng Capital CEO Zhu Pai AttendedBIOCHINA 2026
· March，The 11th Easymount Bio Industry Conference (BIOCHINA 2026)Grandly convened in Suzhou.CEO of Efund Capital, Zhu PaiInvited to attend the core session of the conference, the "Global Investment Forum," and engaged in an in-depth dialogue with industry peers on the theme of "LP-GP Ecosystem Synergy: 'Collaborative' Policies, Capital, and Innovation."
06
Yifeng Milestones
Yifeng Capital CEO Zhu Pai AttendedBIOCHINA 2026
· March，The 11th Easymount Bio Industry Conference (BIOCHINA 2026)Grandly convened in Suzhou.CEO of Efund Capital, Zhu PaiInvited to attend the core session of the conference, the "Global Investment Forum," and engaged in an in-depth dialogue with industry peers on the theme of "LP-GP Ecosystem Synergy: 'Collaborative' Policies, Capital, and Innovation."